已发表的部分文献: 标题:METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.作者:Pan J, Liu F, Xiao X, Xu R, Dai L, Zhu M, Xu H, Xu Y, Zhao A, Zhou W, Dang Y, Ji G;杂志名称:J Exp Clin Cancer Res 标题:Levels and clinical significance of the m6A methyltransferase METTL14 in patients with coronary heart disease.作者:Guo F, He M, Hu B, Li G;杂志名称:Front Cardiovasc Med 标题:Effects of Gestational Arsenic Exposures on Placental and Fetal Development in Mice: The Role of Cyr61 m6A.作者:Song YP, Lv JW, Zhang ZC, Qian QH, Fan YJ, Chen DZ, Zhang H, Xu FX, Zhang C, Huang Y, Wang H, Wei W, Xu DX;杂志名称:Environ Health Perspect 标题:20(S)-ginsenoside Rh2 ameliorates ATRA resistance in APL by modulating lactylation-driven METTL3.作者:Cheng S, Chen L, Ying J, Wang Y, Jiang W, Zhang Q, Zhang H, Wang J, Wang C, Wu H, Ye J, Zhang L;杂志名称:J Ginseng Res 标题:RNA m6A methylation regulatory mechanism of resveratrol in premature senescence cells.作者:Zhang X, Zhu C, Zhang L, Tan L, Cheng W, Li M, Zhang X, Zhang W, Zhang W;杂志名称:Food Sci Nutr Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。